Smarter leaders trust GlobalData

Data Insights Innovation in pharma: neuro-degenerative disease therapies

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

F. Hoffmann-La Roche Ltd

Bristol-Myers Squibb Co

AstraZeneca Plc

Biogen Inc

PTC Therapeutics Inc

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates, and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Neuro-degenerative disease therapies is a key innovation area in the pharmaceutical industry

Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system. These diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and many others. Therapies for neurodegenerative diseases aim to manage symptoms, slow disease progression, and improve the quality of life for individuals affected by these conditions. Cholinesterase inhibitors and memantine are used to manage cognitive symptoms. Levodopa and dopamine agonists help manage motor symptoms. Gene therapy approaches are being developed to correct or replace defective genes for certain genetic neurodegenerative diseases such as spinal muscular atrophy (SMA) and certain forms of familial ALS.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 475 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of neuro-degenerative disease therapies.

Key players in neuro-degenerative disease therapies – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to neuro-degenerative disease therapies

AC Immune is one of the leading patent filers in neuro-degenerative disease therapies. AC Immune is a biopharmaceutical company based in Switzerland that specializes in neurodegenerative diseases, particularly Alzheimer's disease (AD) and other proteinopathies. In 2023, the company received Fast Track designation from the US Food and Drug Administration (FDA) for ACI-24.060 for the treatment of AD. Biogen and F. Hoffmann-La Roche are some of the other key patent filers in neuro-degenerative disease therapies.

In terms of application diversity, Sage Therapeutics leads the pack, while Ionis Pharmaceuticals and Grifols stood in second and third positions, respectively.

By means of geographic reach, Bristol-Myers Squibb held the top position, followed by C2N Diagnostics and Sage Therapeutics.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.